
Superbugs could kill millions more and cost $2tn a year by 2050, models show
A UK government-funded study shows that without concerted action, increased rates of antimicrobial resistance (AMR) could lead to global annual GDP losses of $1.7tn over the next quarter of a century.
The research, by the Center for Global Development thinktank, found the US, UK and EU economies would be among the hardest hit, prompting accusations that recent swingeing aid cuts are self-defeating.
On Thursday, the UK government announced it was axing funding for the Fleming fund, which combats AMR in low- and middle-income countries, as part of wider aid cuts. The Trump administration has confirmed $9bn in cuts to its foreign aid budget, while a number of European countries have also reduced spending on overseas aid.
Anthony McDonnell, the lead author and the research and a policy fellow at the Center for Global Development, said: 'When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends.
'However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research.
'Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries.
'This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns.'
The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and the UK $58.6bn.
According to the Institute for Health Metrics and Evaluation (IHME), deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the US and 184,000 in the UK alone predicted to die each year from antibiotic resistant bugs, while numbers of those becoming seriously ill from drug-resistant bacteria are also expected to jump.
Superbugs increase the number of hospital admissions and lead to longer and more intensive hospital stays, costlier second-line treatments and more complex care, meaning resistant infections are roughly twice as expensive to treat as those for which antibiotics are effective.
The study estimates global health costs of treating AMR could increase by just under $176bn a year, while in the UK, they would rise from $900m to $3.7bn and in the US from $15.5bn to just under $57bn.
Higher rates of resistant bugs would also shrink the UK, EU and US workforces by 0.8%, 0.6% and 0.4% respectively, the study found.
But if countries invest more in tackling superbugs – increasing access to new antibiotics and high-quality treatment of these infections – the US economy would grow $156.2bn a year and the UK $12bn (£9.3bn) by 2050.
Responding to the findings, Dr Mohsen Naghavi, a professor of health metrics at IHME, said: 'Today the threat of AMR is increasing, and without immediate action from all stakeholders the medicines we have access to now could stop working, potentially causing a simple infection to become deadly.'
That would involve policy changes from the US, European and UK governments, the development of new drugs and ensuring everyone understood that antibiotics were ineffective against viruses, he added.
A UK government spokesperson said: 'Our 10-year health plan recognises antimicrobial resistance (AMR) as a major threat and commits to urgently tackle its spread, including through new vaccines.
'We have made important progress - reducing antibiotic use in meat and pioneering a world-first subscription model to incentivise the development of new treatments. We also continue to work closely with international partners to influence global efforts to limit the spread of AMR.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
26 minutes ago
- Reuters
EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy
July 25 (Reuters) - Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' (SRPT.O), opens new tab gene therapy Elevidys for a type of rare muscular dystrophy, the health agency said on Friday. Shares of the company were down nearly 17% at $10.70 in premarket trading. The EU committee's negative opinion comes as yet another setback for the company that is facing increasing regulatory scrutiny after two recent deaths of patients who received Elevidys. Sarepta and its partner outside the U.S., Roche (ROG.S), opens new tab, did not immediately respond to Reuters' requests for comment.


Daily Record
2 hours ago
- Daily Record
Powerful photograph taken by Linlithgow veterinary nurse shortlisted in UK-wide competition
Carena Schmid is representing Scotland with a photograph capturing Rhodesian Ridgeback puppies Venice and Jasper receiving their second vaccinations in a setting carefully adapted to their needs. A powerful photograph taken by a Linlithgow veterinary nurse has been shortlisted in a UK-wide competition by leading home care provider Caremark, as part of its 'What is Care?' photography competition. Launched to mark 20 years of Caremark championing home care in communities, the competition asked the public to capture what care means to them in everyday life, from small gestures to big moments. Out of hundreds of entries, one finalist was chosen from each of the UK's 12 regions, following a rigorous judging process carried out by Caremark's head office. Carena Schmid is representing Scotland with a photograph capturing Rhodesian Ridgeback puppies Venice and Jasper receiving their second vaccinations in a setting carefully adapted to their needs. The image shows the pups in their favourite 'paws-up' position, supported by their owners Claire Staines and Tracey Grant at Lothlorien Dog Services in Linlithgow, where the vaccinations took place — making the experience completely stress-free for the animals. The image is now part of a nationwide public vote on social media to determine the overall winner of the competition. The photographer of the winning entry will receive a £1,000 luxury getaway. Carena said: 'This photo shows how working together can result in a calm, positive care experience — not just for animals, but for people too. 'The owners worked with me and the pups ahead of time to make sure their second vaccinations were completely stress-free. They chose the environment, used their favourite position, gave them treats, and practised gentle handling the week before. 'To me, care means compassion, kindness and adapting what you do to suit the individual, whether human or animal. This image is important to me as it shows how the best level of care can be achieved when everyone works together. 'Little things like this can have a such an important and powerful impact in animal welfare. 'I was shocked and surprised to be selected as a finalist — in a good way! I'm very happy that a photo which promotes positive care for dogs is representing Scotland. If I were to win, I'd love to go somewhere rural in Scotland with my husband and our lovely arthritic Border Collie Miss Darcy and spend some proper quality time together.' Voting is open to the public via Caremark's Facebook page and will close at 9am on September 29. The entry with the highest number of public votes will be announced as the winner shortly after voting closes. Emma Scholes, Caremark's Director of Marketing, said: 'We've been genuinely moved by the creativity and thoughtfulness behind so many of the entries. 'With such an incredible standard from across the country, narrowing it down to just 12 finalists was tough because each photograph carried a personal story, so judging them was emotionally challenging. We felt that Carena's photograph stood out as a powerful reflection of what care can mean. 'This competition marks 20 years of Caremark championing care in communities across the UK. It's about shining a light on what care looks like in everyday life, from small gestures to life-changing support, and how differently people experience and express it. 'Each finalist has brought a unique perspective, and it's been inspiring to see care interpreted so personally through their lens. 'We're excited to now share these images with the public, celebrate the value of care in all its forms, and see who the UK public chooses as their overall winner!' For more information about the competition and to view the finalists' photographs, visit:


Reuters
4 hours ago
- Reuters
EU regulator backs Gilead's twice-yearly injection for HIV prevention
July 25 (Reuters) - The European Union's drugs regulator has recommended approval of Gilead Sciences' (GILD.O), opens new tab lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on Friday. The backing could make it the EU's first twice-yearly HIV prevention option to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents. Lenacapavir offers a long-acting alternative to daily oral pills and other shorter-acting options, aiding critical response to the disease especially among those who struggle with daily adherence, stigma, or access to healthcare. The decision comes more than a month after the treatment received regulatory approval in the U.S., where it is branded as Yeztugo. The World Health Organization recommended the treatment earlier this month as a tool to prevent HIV infection. Any recommendation by the European Medicines Agency's human medicines committee has to be formally approved by the European Commission, which usually follows the regulator's decision. The European Commission's decision on the drug is expected later this year, the company said. If approved,lenacapavir would be granted one additional year of market exclusivity in the EU, and it would be branded as Yeytuo, Gilead said. Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.